CY1114227T1 - Αντισωμα αντι-ilt7 - Google Patents

Αντισωμα αντι-ilt7

Info

Publication number
CY1114227T1
CY1114227T1 CY20131100538T CY131100538T CY1114227T1 CY 1114227 T1 CY1114227 T1 CY 1114227T1 CY 20131100538 T CY20131100538 T CY 20131100538T CY 131100538 T CY131100538 T CY 131100538T CY 1114227 T1 CY1114227 T1 CY 1114227T1
Authority
CY
Cyprus
Prior art keywords
ilt7
antibody
ipc
activity
ifn
Prior art date
Application number
CY20131100538T
Other languages
Greek (el)
English (en)
Inventor
Yumiko Kamogawa
Minkwon Cho
Naoko Arai
Koji Ishida
Original Assignee
Sbi Biotech Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co., Ltd. filed Critical Sbi Biotech Co., Ltd.
Publication of CY1114227T1 publication Critical patent/CY1114227T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
CY20131100538T 2005-12-20 2013-07-02 Αντισωμα αντι-ilt7 CY1114227T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
EP06842945.5A EP1964852B1 (en) 2005-12-20 2006-12-20 Anti-ilt7 antibody

Publications (1)

Publication Number Publication Date
CY1114227T1 true CY1114227T1 (el) 2016-08-31

Family

ID=38188642

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20131100538T CY1114227T1 (el) 2005-12-20 2013-07-02 Αντισωμα αντι-ilt7
CY20141101048T CY1116031T1 (el) 2005-12-20 2014-12-17 Aνti-ilt7 αντισωμα
CY20181101167T CY1121294T1 (el) 2005-12-20 2018-11-07 Αντι-ilt7 αντισωμα

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20141101048T CY1116031T1 (el) 2005-12-20 2014-12-17 Aνti-ilt7 αντισωμα
CY20181101167T CY1121294T1 (el) 2005-12-20 2018-11-07 Αντι-ilt7 αντισωμα

Country Status (29)

Country Link
US (6) US8084585B2 (2)
EP (4) EP3441403A1 (2)
JP (2) JP5020828B2 (2)
KR (3) KR101526934B1 (2)
CN (5) CN101379089B (2)
AU (1) AU2006328470B2 (2)
BR (1) BRPI0620141B1 (2)
CA (2) CA2634116C (2)
CY (3) CY1114227T1 (2)
DK (3) DK2913343T3 (2)
ES (3) ES2526079T3 (2)
HK (1) HK1218126A1 (2)
HR (2) HRP20130494T1 (2)
HU (1) HUE039865T2 (2)
IL (1) IL192266A (2)
LT (1) LT2913343T (2)
ME (1) ME02111B (2)
MX (1) MX2008007682A (2)
NZ (3) NZ616992A (2)
PL (3) PL1964852T3 (2)
PT (3) PT2913343T (2)
RS (2) RS52860B (2)
RU (2) RU2456298C2 (2)
SG (2) SG170749A1 (2)
SI (3) SI2913343T1 (2)
TR (1) TR201816574T4 (2)
UA (1) UA97946C2 (2)
WO (1) WO2007072866A1 (2)
ZA (1) ZA200805850B (2)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
WO2011063237A2 (en) * 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
EP3085387A1 (en) * 2010-04-26 2016-10-26 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
IL281714B2 (en) 2011-04-01 2023-11-01 Immunogen Inc Methods for increasing the effectiveness of FOLR1 cancer therapy
DK2828284T3 (da) 2012-03-20 2019-06-11 Biogen Ma Inc Jcv-neutraliserende antistoffer
ES2706173T3 (es) * 2012-03-20 2019-03-27 Biogen Ma Inc Anticuerpos de neutralización de JCV
JP6403166B2 (ja) * 2012-08-03 2018-10-10 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法
HUE049693T2 (hu) 2012-08-31 2020-10-28 Immunogen Inc Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US10294301B2 (en) * 2013-12-24 2019-05-21 Astellas Pharma Inc. Anti-human BDCA-2 antibody
IL313511A (en) 2014-11-12 2024-08-01 Seagen Inc Compounds acting on glycans and methods of using them
MX382582B (es) * 2015-03-18 2025-03-13 Seagen Inc Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados.
ES2887273T3 (es) * 2015-06-29 2021-12-22 Immunogen Inc Anticuerpos anti-CD123 y conjugados y derivados de los mismos
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
EP3373969A4 (en) 2015-11-12 2019-08-14 Siamab Therapeutics, Inc. GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
MX2018006249A (es) * 2015-11-19 2018-11-09 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-emr2 y metodos de uso.
WO2017130060A1 (en) 2016-01-26 2017-08-03 Ciriello Christopher John Automated dental treatment system
WO2017132486A1 (en) * 2016-01-27 2017-08-03 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
RU2756109C2 (ru) * 2016-03-10 2021-09-28 Виела Байо, Инк. Связывающие ilt7 молекулы и способы их применения
JP6967528B2 (ja) 2016-04-04 2021-11-17 バイオベラティブ ユーエスエー インコーポレイテッド 抗補体Ｂｂ因子抗体及びその使用
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
KR20200042937A (ko) * 2017-08-30 2020-04-24 페인스 테라퓨틱스 인코포레이티드 항-lag-3 항체 및 이의 용도
CN111527105B (zh) 2017-10-11 2024-10-25 美国比奥维拉迪维股份有限公司 诱导补体活性的方法
JP7194481B2 (ja) * 2017-11-17 2022-12-22 メルク・シャープ・アンド・ドーム・エルエルシー 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用
KR20200103751A (ko) 2017-12-20 2020-09-02 라디뮨 테라퓨틱스 인코포레이티드 센트린-1에 대한 항체, 이의 제조 방법, 및 용도
WO2019141092A1 (zh) * 2018-01-18 2019-07-25 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
US20210251721A1 (en) 2018-05-10 2021-08-19 Cyberdontics (Usa), Inc. Automated dental drill
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
MX2022001841A (es) * 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
WO2021070181A1 (en) 2019-10-08 2021-04-15 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
WO2021113702A1 (en) * 2019-12-06 2021-06-10 Viela Bio, Inc. Methods of treatment using ilt7 binding proteins
KR20230004686A (ko) 2020-04-20 2023-01-06 젠자임 코포레이션 인간화 항-보체 인자 Bb 항체 및 그의 용도
WO2022051516A1 (en) 2020-09-03 2022-03-10 Cyberdontics (Usa), Inc. Method and apparatus for cna analysis of tooth anatomy
IL308132A (en) 2021-05-04 2023-12-01 Viela Bio Inc Methods of treatment of autoimmune disorders using ilt7 binding proteins
AU2023312911A1 (en) 2022-07-27 2025-01-02 Viela Bio, Inc. Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
KR20250160358A (ko) * 2023-03-16 2025-11-12 인매진 피티이. 엘티디. Ilt7-표적화 항체 및 그의 용도
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用
WO2026002175A1 (zh) * 2024-06-27 2026-01-02 无锡徕特康生物科技有限公司 靶向ilt7和cd89的髓细胞衔接子抗体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
HU229520B1 (en) * 1999-02-12 2014-01-28 Scripps Research Inst Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
TWI335336B (2) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
US20040241167A1 (en) * 2001-06-25 2004-12-02 Nicole Suciu-Foca Ilt3 and ilt4-related compositons and methods
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
KR20050035511A (ko) * 2001-10-13 2005-04-18 아스테리온 리미티드 폴리펩타이드들을 포함하는 글리코실포스파티딜이노시톨
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
EP2157524A3 (en) 2003-09-03 2010-12-08 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods for identifying, diagnosing, and predicting survival of lymphomas
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Also Published As

Publication number Publication date
US20120135003A1 (en) 2012-05-31
DK2913343T3 (en) 2018-11-26
EP1964852B1 (en) 2013-04-17
NZ616992A (en) 2015-07-31
ES2416716T3 (es) 2013-08-02
ES2699428T3 (es) 2019-02-11
HK1214603A1 (en) 2016-07-29
LT2913343T (lt) 2018-11-26
CY1116031T1 (el) 2017-01-25
JP2012143232A (ja) 2012-08-02
PT2913343T (pt) 2018-11-21
HUE039865T2 (hu) 2019-02-28
HRP20130494T1 (en) 2013-08-31
SG10201602095PA (en) 2016-05-30
PT1964852E (pt) 2013-07-10
AU2006328470A2 (en) 2008-10-09
SG170749A1 (en) 2011-05-30
JP5020828B2 (ja) 2012-09-05
CA2634116A1 (en) 2007-06-28
US20130259872A1 (en) 2013-10-03
KR101585532B1 (ko) 2016-01-14
EP1964852A1 (en) 2008-09-03
CN105111311B (zh) 2019-10-18
US8084585B2 (en) 2011-12-27
CA2994756C (en) 2020-10-27
PL2532681T3 (pl) 2015-03-31
IL192266A0 (en) 2008-12-29
ME02111B (me) 2015-10-20
ZA200805850B (en) 2009-04-29
MX2008007682A (es) 2008-10-23
EP3441403A1 (en) 2019-02-13
CN105111311A (zh) 2015-12-02
IL192266A (en) 2014-09-30
HK1179638A1 (en) 2013-10-04
NZ569910A (en) 2012-06-29
TR201816574T4 (tr) 2018-11-21
JP5420688B2 (ja) 2014-02-19
CA2994756A1 (en) 2007-06-28
RS53752B1 (sr) 2015-06-30
EP2913343A1 (en) 2015-09-02
PL1964852T3 (pl) 2013-09-30
EP1964852A4 (en) 2010-02-24
CN110776566A (zh) 2020-02-11
PL2913343T3 (pl) 2019-03-29
CN103360492A (zh) 2013-10-23
US20090280128A1 (en) 2009-11-12
RU2599450C2 (ru) 2016-10-10
RU2012112046A (ru) 2013-10-10
UA97946C2 (ru) 2012-04-10
BRPI0620141A2 (pt) 2011-11-01
CN101379089A (zh) 2009-03-04
CY1121294T1 (el) 2020-05-29
CN120718150A (zh) 2025-09-30
CN110776566B (zh) 2025-07-15
EP2913343B1 (en) 2018-08-08
RU2456298C2 (ru) 2012-07-20
HK1218126A1 (zh) 2017-02-03
US20160130343A1 (en) 2016-05-12
KR20080090430A (ko) 2008-10-08
KR101526934B1 (ko) 2015-06-26
PT2532681E (pt) 2014-12-23
HK1124347A1 (en) 2009-07-10
KR101624587B1 (ko) 2016-05-26
EP2532681A1 (en) 2012-12-12
RS52860B (sr) 2013-12-31
HRP20141226T1 (hr) 2015-02-27
BRPI0620141B1 (pt) 2024-04-30
SI1964852T1 (sl) 2013-09-30
SI2913343T1 (sl) 2019-01-31
SI2532681T1 (sl) 2015-03-31
KR20140053232A (ko) 2014-05-07
AU2006328470A1 (en) 2007-06-28
US20170204179A1 (en) 2017-07-20
NZ599683A (en) 2013-11-29
JPWO2007072866A1 (ja) 2009-06-04
AU2006328470B2 (en) 2012-08-16
WO2007072866A1 (ja) 2007-06-28
DK2532681T3 (en) 2015-01-05
KR20150031485A (ko) 2015-03-24
RU2008129715A (ru) 2010-01-27
US20200339682A1 (en) 2020-10-29
CN101379089B (zh) 2013-08-07
CA2634116C (en) 2018-03-27
US8470992B2 (en) 2013-06-25
ES2526079T3 (es) 2015-01-05
EP2532681B1 (en) 2014-10-01
DK1964852T3 (da) 2013-07-08

Similar Documents

Publication Publication Date Title
CY1114227T1 (el) Αντισωμα αντι-ilt7
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
CY1123618T1 (el) Πολυπεπτιδια αντισωματα που ανταγωνιζονται cd40l
PA8847001A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
PE20220708A1 (es) Anticuerpos anti-cd73
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1109143T1 (el) Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενες σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτητας
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1112446T1 (el) Θεραπευτικες ουσιες που βασιζονται σε αντιγονα με ενισχυμενη δραση αdcc
AR080663A1 (es) Proteinas de union especificas y sus usos
GT200500205A (es) Nuevos anticuerpos anti-igf-ir y sus usos
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MX2010002683A (es) Poblaciones de anticuerpos homogeneos.
BRPI0711908B8 (pt) anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
CY1111819T1 (el) Αντισωμα εναντι epcam και χρησεις αυτου
CR20120087A (es) Anticuerpos del antígeno carcinoembrionario (cea)
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
FR2933773B1 (fr) Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
PE20071312A1 (es) Anticuerpos contra il-22 humana